Single Blood Test Can Detect 50 Types of Cancer In Early Stages

Cancer therapy is seeing a silver lining with the launch Grail’s Galleri blood test, which claims that it has the ability to detect as many as 50 types of cancer.

The blood test has yet to gain approval from the U.S. Food and Drug Administration (FDA), which has so far issued a Breakthrough Therapy Designation, but GRAIL has already signed a deal with the National Health Service (NHS) in the U.K. to support programs that hope to detect cancer early and save more lives. 

Despite the absence of the FDA’s seal, the New York State Department of Health also issued a go-ahead to use Galleri for early cancer detection in September. The test is now available to residents by prescription, in addition to existing single cancer screening tests. 

“The approval of the New York State Department of Health marks a significant regulatory milestone for GRAIL and confirms the high standard for validation of our rigorous approach to test development, and the high quality of our clinical laboratory,” commented Dr. Josh Ofman, chief medical officer and head of external affairs at GRAIL, in a statement. 

To Read the Complete Article at Pharmacy Times Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by tatsianama from Depositphotos

Comments are closed.